Skip to main content
Premium Trial:

Request an Annual Quote

Genome Compiler, DNA2.0 Partner on Synthetic Biology Software

NEW YORK (GenomeWeb) – Genome Compiler today announced a collaboration under which it will integrate DNA2.0's gene synthesis services into its computer-aided synthetic biology design platform.

"Direct connection to DNA2.0 services will simplify the design to order user experience, giving a more streamlined approach to the programming of living things," Omri Drory, CEO of Genome Compiler, said in a statement.

Genome Compiler, with offices in Los Altos, Calif. and Tel-Aviv, Israel, is a software developer creating computer-aided design and collaboration platforms for the synthetic biology industry.

Menlo Park, Calif.-based bioengineering firm DNA2.0 offers an integrated pipeline for designing, optimizing, and synthesizing genes and proteins.

In March, DNA2.0 licensed the technology underlying its Gene Designer software to Genome Compiler, ending a patent dispute between the two firms.

Financial and other terms of the deal were not disclosed.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.